Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Non Operating Income: 2020-2025

Historic Non Operating Income for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to $2.7 million.

  • Foghorn Therapeutics' Non Operating Income fell 43.93% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year decrease of 3.39%. This contributed to the annual value of $16.1 million for FY2024, which is 17.20% up from last year.
  • Latest data reveals that Foghorn Therapeutics reported Non Operating Income of $2.7 million as of Q3 2025, which was down 16.10% from $3.2 million recorded in Q2 2025.
  • In the past 5 years, Foghorn Therapeutics' Non Operating Income ranged from a high of $4.7 million in Q3 2024 and a low of $144,000 during Q1 2021.
  • Moreover, its 3-year median value for Non Operating Income was $3.5 million (2023), whereas its average is $3.6 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first soared by 9,514.29% in 2021, then tumbled by 43.93% in 2025.
  • Quarterly analysis of 5 years shows Foghorn Therapeutics' Non Operating Income stood at $2.0 million in 2021, then soared by 48.59% to $3.0 million in 2022, then grew by 11.27% to $3.3 million in 2023, then spiked by 34.87% to $4.5 million in 2024, then plummeted by 43.93% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $3.2 million for Q2 2025, and $4.1 million during Q1 2025.